Otonomy Competitors

AC Immune (NASDAQ:ACIU) and Otonomy (NASDAQ:OTIC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares AC Immune and Otonomy's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for AC Immune and Otonomy, as provided by MarketBeat.com.

AC Immune presently has a consensus target price of $11.00, suggesting a potential upside of 42.30%. Otonomy has a consensus target price of $8.10, suggesting a potential upside of 179.31%. Given Otonomy's higher probable upside, analysts plainly believe Otonomy is more favorable than AC Immune.

Volatility & Risk

AC Immune has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Otonomy has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Insider and Institutional Ownership

27.7% of AC Immune shares are owned by institutional investors. Comparatively, 72.3% of Otonomy shares are owned by institutional investors. 16.1% of Otonomy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares AC Immune and Otonomy's top-line revenue, earnings per share and valuation.

AC Immune has higher revenue and earnings than Otonomy. Otonomy is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats AC Immune on 7 of the 13 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Geron's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Geron, as reported by MarketBeat.

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Geron has a consensus price target of $4.00, suggesting a potential upside of 124.72%. Given Otonomy's higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Geron.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Geron has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 55.5% of Geron shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 7.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Geron's top-line revenue, earnings per share (EPS) and valuation.

Otonomy has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats Geron on 8 of the 13 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Evelo Biosciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Evelo Biosciences, as reported by MarketBeat.

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Evelo Biosciences has a consensus price target of $18.25, suggesting a potential upside of 56.92%. Given Otonomy's stronger consensus rating and higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Evelo Biosciences.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 84.6% of Evelo Biosciences shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 7.3% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Evelo Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Otonomy has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats Evelo Biosciences on 11 of the 13 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and XBiotech's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and XBiotech, as reported by MarketBeat.

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. XBiotech has a consensus price target of $18.00, suggesting a potential downside of 4.26%. Given Otonomy's higher possible upside, equities research analysts plainly believe Otonomy is more favorable than XBiotech.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 14.8% of XBiotech shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 31.0% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and XBiotech's top-line revenue, earnings per share (EPS) and valuation.

XBiotech has lower revenue, but higher earnings than Otonomy.

Summary

XBiotech beats Otonomy on 6 of the 11 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Relmada Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Relmada Therapeutics, as reported by MarketBeat.

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Relmada Therapeutics has a consensus price target of $63.3333, suggesting a potential upside of 88.16%. Given Otonomy's stronger consensus rating and higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Relmada Therapeutics.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 64.3% of Relmada Therapeutics shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 9.3% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Relmada Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Relmada Therapeutics has lower revenue, but higher earnings than Otonomy. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats Relmada Therapeutics on 9 of the 12 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Flexion Therapeutics (NASDAQ:FLXN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Flexion Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Flexion Therapeutics, as reported by MarketBeat.

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Flexion Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 82.76%. Given Otonomy's higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Flexion Therapeutics.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Flexion Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 17.0% of Flexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Flexion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Otonomy has higher earnings, but lower revenue than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.